Regorafenib: New Option for Advanced Gastroesophageal Cancer?
SAN FRANCISCO — Patients with refractory advanced gastroesophageal cancer (AGOC) have a poor prognosis, with limited options following failure of second-line therapy. New data showing improved survival suggest that regorafenib (Stivarga) may offer a new treatment option in these patients.Source: Medscape
Ignoring Back Pain Can Be a Big Pancreatic Cancer Mistake, Doctors Say
The symptoms of pancreatic cancer may be subtle, varied, or—in the early stages of the disease—non-existent. That's why "pancreatic cancer is the most lethal cancer in the human body, with overall five-year survival rates at just about seven percent despite all the advances over the past decades," according to the Mayo Clinic News Network. "There are no telltale signs for pancreatic cancer, and symptoms like weight loss, abdominal pain, jaundice, and appetite loss are nonspecific."Source: Yahoo Life
Kirstie Alley and Colon Cancer: The Early Signs You Shouldn't Ignore
Actor Kirstie Alley has died after being diagnosed with colon cancer earlier this year. Colon cancer, also known as colorectal cancer, is the third most common type of cancer in the United States and globally. In the U.S. over 151,000 people will develop the disease in 2022.Source: Healthline
Opinion: The deadly consequences for Black patients of blaming the victim
The impact of COVID-19 has underscored what health statistics have shown for decades: When it comes to serious illness in the United States, nonwhite people are likelier to die than white people. This phenomenon is often attributed to poorer health among low-income minorities, but on closer inspection, this explanation falls short. Our team at Yale University has researched treatment disparities in gastrointestinal cancers, including cancers of the pancreas, colon, liver and other organs of the digestive system. Our findings , published recently, show that Black cancer patients do not receive the same quality surgery and follow-up therapies as white patients. This subpar care is not attributable to the patient’s medical condition. It is attributable to the patient’s skin color.Source: CT Post
Know the Warning Signs of Stomach Cancer, as Toby Keith Reveals Diagnosis
Dr. Bershadskiy says, "Some but not all studies from Europe, Asia and North America have found intake of fruits and vegetables to be protective, fruits likely have a higher benefit. Reducing the risk of stomach cancer by 30-40%. The protective benefits of fruits and vegetables are likely related to their vitamin C content, which is thought to reduce the formation of carcinogenic N-nitro compounds inside the stomach.Source: ETNT Health
New Chief of Surgical Oncology Appointed at Smilow Cancer Hospital and Yale Cancer Center
Kiran Turaga, MD, MPH, has been appointed Chief of Surgical Oncology for the Department of Surgery, Yale School of Medicine, and Assistant Medical Director for the Clinical Trials Office at Yale Cancer Center.
Advancing Novel Pancreatic Cancer Research
A CAREER DEVELOPMENT GRANT FROM THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) HELPED YALE CANCER SCIENTIST LUISA ESCOBAR-HOYOS, MSC, PHD, EARN TWO MAJOR, MULTI-YEAR FEDERAL GRANTS TO FURTHER DEVELOP HER RESEARCH.Source: American Association for Cancer Research
The Lustgarten Foundation Announces Mandar Muzumdar, MD, to Receive a 2022 Innovation and Collaboration Program Grant
The Lustgarten Foundation announced today that a 2022 Innovation and Collaboration Program grant will be awarded to Mandar Muzumdar, MD, Co-Director of Pancreas Program, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center for his study "Dietary oleic acid reprograms pancreatic lipid metabolism to drive cancer development."Source: Lustgarten Foundation
Do You Need a Colonoscopy? Here's What a Major New Study Found
A new study on colonoscopies found that those who received the screening had a 31% lower chance of being diagnosed with colorectal cancer. All Americans are advised to start getting colonoscopies at age 45. The researchers say that the effectiveness of colonoscopies is lower than the estimates from past studies.Source: Healthline
Yale Cancer Center Expert Says Study Suggesting Colonoscopy Benefits Are Overestimated is Misleading
A new study out of Norway suggests that the benefits of using a colonoscopy as a cancer screening tool have been overestimated — but an expert at the Yale Cancer Center still urges people to get one.Source: WTNH
Yale Cancer Center’s Luisa Escobar-Hoyos Awarded NIH High-Risk, High-Reward Grant
Luisa Escobar-Hoyos, MSc, PhD, Assistant Professor of Therapeutic Radiology and Molecular Biophysics and Biochemistry at Yale, was awarded a New Innovator Award from the National Institutes of Health (NIH) through its High-Risk, High-Reward Research Program.
Pamela Kunz, MD on 1999 Simone’s Maxims
Pamela Kunz, MD, associate professor (medical oncology) and vice chief of Diversity, Equity, and Inclusion (medical oncology) writes that, “I distinctly remember being told by mentors to read the original 1999 Simone’s Maxims – as these maxims were put on a pedestal as the truths of how to navigate academic medicine.”
Sex Differences in Gastrointestinal Cancer
With this year's Wendy U. and Thomas C. Naratil Pioneer Award and co-funding from the Yale Cancer Center, Dr. Pamela Kunz is conducting one of the first studies to examine sex differences in treating neuroendocrine neoplasms (NENs), a rare form of cancer often found in the gastrointestinal tract.
Pamela L. Kunz, MD, Reviews Results of Temozolomide as Monotherapy or in Combination With Capecitabine in Advanced Pancreatic NETs
Pamela L. Kunz, MD, associate professor of Internal Medicine; director of the Center for Gastrointestinal Cancers at Smilow Cancer Center and Yale Cancer Center; chief of Gastrointestinal Medical Oncology; and vice chief of Diversity, Equity, and Inclusion at Yale School of Medicine, spoke with CancerNetwork® at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting about the results of a phase 2 trial (NCT01824875) which analyzed temozolomide (Temodar) as monotherapy or in combination with capecitabine for patients with advanced pancreatic neuroendocrine tumors.1 Results indicated that the combination regimen should be considered a standard of care option in the setting of pNETsSource: Cancer Network